Details of the Drug

General Information of Drug (ID: DMYXDB9)

Drug Name

NN-8828

Synonyms

NNC-114-0005; NNC-0114-0000-0005; Anti-IL-21 (inflammation), Novo Nordisk; MIL-21 monoclonal antibody (autoimmune/chronic inflammatory disease), ZymoGenetics; Anti-IL-21 mAb (autoimmune/chronic inflammatory disease), Novo Nordisk; Anti-IL-21 mAb (autoimmune/chronic inflammatory disease), ZymoGenetics; Anti-IL-21 monoclonal antibody (autoimmune/chronic inflammatory disease), ZymoGenetics

Indication

Disease Entry	ICD 11	Status	REF
Autoimmune diabetes	5A10	Phase 1	[1]
------------------------------------------------------------------------------------

Drug Type

Antibody

Cross-matching ID

TTD ID: D05ZSX

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Interleukin-21 (IL21)	TT9QEJ6	IL21_HUMAN	Not Available	[2]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Autoimmune diabetes

ICD Disease Classification

5A10

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Interleukin-21 (IL21)	DTT	IL21	2.92E-02	0.09	1.42

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

References

1	ClinicalTrials.gov (NCT01208506) First-in-Man Trial of NNC114-0005 in Healthy Subjects and Subjects With Rheumatoid Arthritis. U.S. National Institutes of Health.
2	Handbook of Therapeutic Antibodies. 2014. 1. Page(995).